Citations

Clear

4510 citation(s) found for "Oh, Scott".

FANCM restrains structural genome evolution and defines a synthetic lethal dependency in BRCA1 -deficient breast cancer
Panday, Arvind , Ramadan, Farah, Shah, Sameer Bikram , Subedi, Ujwal, Stephens, Zachary, Venkatachalam, Annapoorna , Yadav, Neelima, Pandit, Vickky, Dubey, Sadhana, Latka, Sarah, Villanueva, Hugo , Dubey, Sadhana, Latka, Sarah , Kaufmann, Scott H. , Panday, Arvind

Mayo Clinic

No container title available | September 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.06.749689 | PMID 42818548 Get It

Abstract BRCA1 -deficient cancers experience persistent replication stress and structural genome instability yet retain the capacity for sustained proliferation, implying reliance on compensatory genome-maintenance mechanisms. Here, we establish BRCA1–FANCM synthetic lethality in human BRCA1 -deficient breast cancer and exploit temporally controlled FANCM depletion to capture genome evolution over successive cell divisions before declining cellular fitness becomes limiting. We show that FANCM restrains genome-wide structural variation in BRCA1 -deficient breast cancer cells under endogenous replication stress. FANCM loss amplifies the characteristic BRCA1 -associated short tandem duplication (TD) phenotype while permitting larger, including megabase-scale, TDs and diverse rearrangements to emerge. Newly emerged TDs preferentially associate with Pol II-occupied regions, and FANCM depletion increases proximity between the replication machinery and elongating RNAPII in BRCA1 -mutant breast cancer cells, linking FANCM-mediated genome protection to transcription–replication encounters. BRCA1 -altered human tumors with low FANCM expression recapitulate key features of this phenotype, while genome–transcriptome integration links newly emerged SVs to configuration-dependent local transcriptional changes. Together, these findings establish FANCM as a replication-stress safeguard coupling survival to restraint of structural genome evolution.
Comparative Dosing of Bevacizumab for Radiation Necrosis: Impact of Tumor Type on Edema Response
Schultz, Sydney E., Labib, Milisia, Breit, Jeff, Barreto, Jasón, Mead‐Harvey, Carolyn , Behairy, Mohamad, Nurioglu, Aylin, White, Jessica, Valerius, Allison , Taraba, Jodi L. , Soefje, Scott, Hoefs, Gena, Caron, Samantha, Ruff, Deborah, Uhm, Joon, Lachance, Daniel, Kizilbash, Dr Sani, Campian, Jian, Geyer, Susan, Neth, Bryan, Sener, Ugur, Schultz, Sydney , Barreto, Jason N. , Behair, Mohamad, White, Jessica B. , Karbhari, Nishika , Taraba, Jodi L , Soefje, Scott A. , Hoefs, Gena E, Caron, Samantha, Ruff, Michael W. , Uhm, Joon H. , Lachance, Daniel Honore , Kizilbash, Sani H. , Campian, Jian , Geyer, Susan M. , Neth, Bryan J. , Sener, Uğur

Mayo Clinic

No container title available | September 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10795946/v1 Get It

Abstract Purpose Bevacizumab is an effective treatment for radiation necrosis; dose dependent radiographic and edema response data are lacking. Methods Multicenter, retrospective cohort study of adult patients with primary central nervous system tumors or brain metastases who received bevacizumab for radiation necrosis between June 2021 and July 2024. Patients were grouped by bevacizumab dose (7.5 mg/kg vs 10 mg/kg administered every three weeks). Primary outcome was edema response, assessed by a blinded neuro-oncologist. Secondary outcomes included contrast enhancing disease response, clinical response, adverse events, treatment discontinuation, and re-dosing for recurrent radiation necrosis. Analyses were performed with and without adjustment for tumor type. Results 104 patients were included (7.5 mg/kg, n = 53; 10 mg/kg, n = 51). Edema response differed between dosing groups in unadjusted analyses (p = 0.032), favoring the 7.5 mg/kg cohort; however, this association was attenuated after adjustment for tumor type. Contrast enhancing disease response did not differ between groups in either unadjusted or adjusted analyses (p = 0.43). Clinical response was higher in the 7.5 mg/kg group (65.2% vs 37.8%, p = 0.013). Tumor type differed significantly between cohorts (p < 0.001), with more primary CNS tumors in the 10 mg/kg group. Rates of adverse events, treatment discontinuation, and re-dosing were similar. Conclusions While lower-dose bevacizumab was associated with greater edema reduction in unadjusted analyses, this effect was attenuated after accounting for tumor type. Importantly, 7.5 mg/kg dosing appeared sufficient for achieving edema control and contrast enhancing disease response. These findings support an individualized approach to bevacizumab dosing in radiation necrosis and highlight the need for prospective, tumor-stratified studies.
Nuclear Cathepsin L Remodels the Replication Machinery to Create a Therapeutic Vulnerability in Ovarian Cancer
Jin, Ling, Balakrishnan, Karthik , Hou, Xiaonan , VanBlaricom, Jamison L., Lee, Sun-Hee, Oberg, Ann L. , Weroha, John, Shridhar, Viji, Thirusangu, Prabhu , Jin, Ling, Rao, Shruti , Balakrishnan, Karthik, Lee, Sun-Hee , Kaufmann, Scott H. , Bakkum‐Gamez, Jamie N. , Shridhar, Viji

Mayo Clinic

No container title available | September 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.02.748933 | PMID 42922689 Get It

Abstract Therapeutic resistance in ovarian cancer is frequently driven by persistent replication stress, yet the molecular mechanisms that convert replication stress into a therapeutically exploitable vulnerability remain incompletely understood. Here, we identify drug-induced nuclear cathepsin L (nCTSL) as a previously unrecognized regulator of replication stress and DNA repair. Clofarabine (CLF) combined with the ATR inhibitor AZD6738, or the CHK1 inhibitor prexasertib promoted nuclear accumulation of CTSL, where it remodeled the replication machinery through degradation of CCNE1, MCM3, MCM6, and geminin, accompanied by loss of RAD51 and 53BP1 and increased γH2AX and phospho-RPA2. DNA fiber analysis demonstrated marked inhibition of replication fork progression following CLF-based combinations, whereas CTSL depletion accelerated fork progression and abolished therapy-induced replication stress. Reconstitution with the nuclear M1F CTSL isoform restored replication restraint, confirming a direct role for nuclear CTSL in regulating replication dynamics. GFP-based DNA repair reporter assays further revealed that CLF-based combinations suppress DNA repair competence in a CTSL-dependent manner, indicating that nuclear CTSL couples replication stress amplification with functional inhibition of repair pathways. Functionally, CLF-based combinations selectively targeted transformed fallopian tube secretory epithelial cells while sparing non-transformed counterparts, demonstrated broad activity in patient-derived ovarian cancer ascites spheroids, and significantly inhibited tumor growth and prolonged survival in vivo . Collectively, our findings identify nuclear CTSL as a mechanistic driver of replication stress that remodels the replication machinery, impairs DNA repair, and creates a therapeutically exploitable vulnerability in ovarian cancer. We propose that nuclear CTSL promotes a transition from replication competence to replication catastrophe, thereby establishing a conceptual framework for biomarker-guided therapeutic strategies targeting CTSL-dependent replication stress.
Machine learning-based prediction of hypotension following emergency intubation
Sujanyal, Saurabh Ashok , Omercikoglu, Elcin , Alazab, Heba, Handral, Megha, LEE, JIEUN , Saunders, Hollie , Arunachalam, S P , Sujanyal, Saurabh , Alazab, Heba, Handral, Megha Sasidhar, Arunachalam, Shivaram P. , Helgeson, Scott A.

Mayo Clinic

BMJ Innovations | September 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: bmjinnov-2026-001625

10.1136/bmjinnov-2026-001625 Get It

Introduction Post-intubation hypotension (PIH) is a frequent complication of emergency endotracheal intubation and is associated with increased mortality. Early identification of high-risk patients remains challenging, and existing prediction tools demonstrate moderate accuracy. Objective We aim to identify predictors of PIH and develop machine learning models for pre-intubation risk stratification. Methods We conducted a multicentre retrospective study across 3 Mayo Clinic hospitals, including 600 adults undergoing urgent intubation in the intensive care unit. PIH was defined by mean arterial pressure<65 mm Hg, systolic blood pressure (SBP)<80 mm Hg or ≥40% decline or vasopressor initiation/escalation within 30 min. Three model frameworks were developed: Shock Indices (SIs), Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA), incorporating demographic, haemodynamic, laboratory and sedation variables. Various machine learning algorithms were applied to analyse the three models. Results PIH occurred in 46% of patients included in the study. In the SIs model, stepwise logistic regression achieved an area under the curve (AUC) of 0.76. The APACHE II framework showed the strongest performance, with random forest achieving an ROC AUC of 0.82 and the ensemble model demonstrating the highest overall discrimination (Receiver operator Curve [ROC] AUC 0.83) with favourable accuracy and F1 metrics. The SOFA framework showed moderate performance, with an ensemble ROC AUC of 0.73. Key predictors included pre-intubation vasopressor use, SBP, platelet count and haematological parameters. Conclusions Machine learning models using routinely available pre-intubation data showed potential to predict PIH in this retrospective proof-of-concept study. These findings support further development of anticipatory artificial intelligence-driven risk stratification in critical care, but the models should not be considered ready for bedside implementation until they undergo prospective validation in larger, independent and more diverse cohorts.
From Housing to Hotspots: Integrating a Housing-Based Measure of Individual Socioeconomic Status with Geospatial Analysis to Target Colorectal Cancer Screening in Rural Communities
Yao, Rebecca , Beenken, Madison, Watson, Dave , Wheeler, Philip H., Finch, Mike, Kelleher, Dan , Anil, Gokhan , Anderson, Trent, Madden, Kathy A., Okuno, Scott H. , Odedina, Folakemi T., Park, Eunice , Dugani, Sagar B., Sosso, Jessica , Sabarish, Shivani , Singh, Gurpreet, Lugo-Fagundo, Nahyr, Kim, W. Ray, Walker-Mcgill, Cheryl L., Juhn, Young J. , Lynch, Brian , Wi, Chung‐Il , Madden, Kathy A., Westfall, Erin , Sharma, Pravesh , Dugani, Sagar B. , Foss, Randy , Hidaka, Brandon H. , Singh, Gurpreet, Howick V, James F , Calvin, Andrew D. , Walker-McGill, Cheryl Lynn, Rennert, Lior , Cerhan, James R. , Beenken, Madison J, Kelleher, Dan P., Westfall, Erin C, Park, Eunice Y., Sharma, Pravesh , Foss, Randy M, Sosso, Jessica L

Mayo Clinic

No container title available | September 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.28.26361444 | PMID 42922856 Get It

ABSTRACT Purpose This study assesses the association between colorectal cancer (CRC) screening and a validated, housing-based measure of individual-level socioeconomic status (SES, called HOUSES hereafter) within rural communities and determines whether HOUSES-integrated geospatial analysis can be used to tailor interventions. Methods We used CRC screening data from a subset of Mayo Clinic Midwest patients living in cities without ready access to routine care in the Mayo Clinic Health System in 2019 to represent rural communities. At the individual level, we assessed the association between CRC screening rates and the HOUSES index, adjusting for age, sex, race/ethnicity, comorbidity, distance from home address to clinic, and area deprivation index, using a multilevel mixed-effects logistic regression model. Additionally, we conducted geospatial analysis to examine the correlation between hotspots of 1) lower CRC screening rates and 2) lower SES of the subject population (HOUSES quartile 1). Findings Among 34,489 individuals (median age 64.0 years, 52.4% female), those with the lowest SES (HOUSES Q1) had 37% lower odds of being CRC screening adherent than those with the highest SES (HOUSES Q4) (adj. OR [95% CI]: 0.63 [0.58-0.69]). In the 14 identified HOUSES Q1 hotspots, there was a significant correlation in counts of HOUSES Q1 and low CRC screening (correlation coefficient=0.81). Conclusion Lower SES was significantly associated with lower CRC screening among rural populations. HOUSES-enabled geospatial analysis identified geographic hotspots with lower CRC screening rates for targeted interventions to address disparities in CRC screening in rural communities. HOUSES may be a useful digital tool for cancer preventive care and research.
Phase 2 Study of Futibatinib in Combination with Pembrolizumab in Patients with FGF19 expressing Advanced Hepatocellular Carcinoma
Tran, Nguyen H, Palmer, Mathias Earl, Ulrich, Angela, McCue, Shaylene , Majeed, Umair, Halfdanarson, Thorvardur R, Carr, Ryan, Fonkoua, Lionel Aurelien Kankeu, Washburn, Leslie, Conboy, Caitlin, Torbenson, Michael, Starlinger, Patrick, Hallemeier, Christopher, Revzin, Alexander, Goenka, Ajit H. , Tran, Nguyen , Palmer, Mathias E , Mahipal, Amit , Ma, Wen Wee , Babiker, Hani , Halfdanarson, Thorvardur R , McWilliams, Robert R , Jin, Zhaohui , Carr, Ryan M , Fonkoua, Lionel Aurelien A Kankeu , Washburn, Leslie A , Conboy, Caitlin B , Graham, Rondell P , Starlinger, Patrick , Jethwa, Krishan , Goenka, Ajit Harishkumar , Venkatesh, Sudhakar K , Sonbol, Mohamad B , Bekaii-Saab, Tanios S , Roberts, Lewis R , Heimbach, Julie K , Ou, Fang-Shu , Tran, Nguyen H. , Mahipal, Amit , Wee, Wen , Babiker, Hani M. , Majeed, Umair , Hálfdánarson, Þorvarður R. , McWilliams, Robert R. , Jin, Zhaohui , Fonkoua, Lionel Aurelien Kankeu , Conboy, Caitlin B. , Graham, Rondell P. , Torbenson, Michael , Starlinger, Patrick , Jethwa, Krishan R. , Hallemeier, Christopher Leigh , Revzin, Alexander , Thompson, Scott M. , Venkatesh, Sudhakar K. , Sonbol, Mohamad Bassam , Borad, Mitesh J. , Bekaii‐Saab, Tanios , Gores, Gregory J. , Roberts, Lewis R. , Heimbach, Julie K. , Ou, Fang‐Shu

Mayo Clinic

The Oncologist | August 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/oncolo/oyag343 | PMID 42640574 Get It

Abstract Background Optimal treatment following first-line immunotherapy for advanced hepatocellular carcinoma (HCC) remains uncertain. This study evaluated futibatinib, a pan-FGFR inhibitor, combined with pembrolizumab in previously treated patients with FGF19-expressing HCC. Methods Eligible patients were ≥18 years old with advanced HCC, prior systemic therapy, Child-Pugh A-B7 liver function, ECOG 0–2, and FGF19 overexpression. Patients received futibatinib 20 mg orally daily plus pembrolizumab 200 mg intravenously every 3 weeks. The primary endpoint was progression-free survival at 6 months (PFS6). Secondary endpoints included overall survival (OS), objective response rate (ORR), quality of life, and safety. Results Between August 2021 and March 2024, 14 patients enrolled and 13 were evaluable. Median age was 72 years (range, 60–87), 53.8% were male, 92.3% had Child-Pugh A liver function, and all had received prior immunotherapy. Median progression-free survival was 15 weeks (95% CI, 9.0–NE), with a PFS6 rate of 23.1% (95% CI, 8.6–62.3%). ORR was 0% (95% CI, 0–24.7%), while stable disease was observed in 53.9% of patients. Median OS was 55.7 weeks (95% CI, 47.3–NE). Grade ≥3 adverse events occurred in 69.2% of patients, and grade ≥4 adverse events in 15.4%. One grade 5 event (acute-on-chronic kidney injury) was deemed unrelated to treatment. Common adverse events included hyperphosphatemia, fatigue, diarrhea, elevated transaminases, dry eye, nail changes, rash, and oral mucositis. Conclusions Futibatinib plus pembrolizumab demonstrated an acceptable safety profile but did not meet efficacy thresholds supporting further study in FGF19-expressing HCC. Effective post-immunotherapy treatment strategies remain an unmet need.
Epidemiologic Study of Transfusion-Related Alpha-Gal Syndrome
Kaufman, Richard M., Hoen, Anne G., Khan, Jenna, Knudson, C. Michael, Romero, Andres E. Mindiola, Mo, Allison , Takanashi, Minoko , Collaborative, UPTICK Study Group; for the Biomedical Excellence for Safer Transfusion (BEST), Cardigan, Rebecca, Stanworth, Simon J., Commins, Scott P. , Scherer, Emily A., Davenport, Robertson D., Afraz, Sajjad, Andrews, Jennifer , Casey, John, Sullivan, Jensyn Cone , Cousins, Clara C. , Giorgi, Valeria De , Delaney, Meghan, DelBaugh, Regina M. , Gilstad, Colleen W. , Gofton, Alexander , Hill, Kate, Hogan, Keenan , Humbrecht, Catherine , Ikeda, Kazuhiko, Javanbakht, Ayda, Juskewitch, Justin E, Wojtowicz, Monique M. Menzies, Miller, Maureen J., Mills, Georgia, Nelson, Anna C. , Pauly, Marie C., Poisson, Jessica , Raval, Jay S., Samy, Nikitha, Sato, Tomohiko, Takeda, Yoshinori , Thibodeaux, Suzanne R. , Nunen, Sheryl van, Virk, Mrigender S., West-Mitchell, Kamille, Yamanouchi, Jun, Yoshihara, Satoshi, Zheng, X. Long, Ziman, Alyssa, Cone Sullivan, Jensyn , Kaufman, Richard Max , Hoen, Anne Gatewood , Knudson, Charles Michael , Metcalf, Ryan A. , Schäfer, Richard , Dunbar, Nancy M. , Cardigan, Rebecca A. , Stanworth, Simon J., Scherer, Emily A. , Cervinski, Mark A , Arai, Yasuyuki , Brugnara, Carlo , Allen, Elizabeth S. , Aurich, Konstanze , Casey, John , Cohn, Claudia S. , Crowe, Elizabeth P , Delaney, Meghan , Hendrickson, Jeanne E. , Hill, Kate, Ikeda, Kazuhiko , Jacquot, Cyril , Javanbakht, Ayda , Juskewitch, Justin E. , Lu, Wen , Wojtowicz, Monique Menzies , Miller, Maureen J. , Nelson, Anna , Pagano, Monica B. , Pauly, Marie-Christin , Saifee, Nabiha H , Sato, Tomohiko, Takeda, Yoshinori, Tiberghien, Pierre , Nunen, Sheryl van, Virk, Mrigender , Wood, Erica M , Yoshihara, Satoshi , Zheng, X. Long, Ziman, Alyssa

Mayo Clinic

JAMA Internal Medicine | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamainternmed.2026.3983 | PMID 42636004 Get It

Importance Recent case reports suggest that B antigen–containing blood products may be associated with anaphylactic transfusion reactions in recipients with preformed immunoglobulin E to galactose- α -1,3-galactose (alpha-gal). Objective To test the association of local alpha-gal syndrome (AGS) prevalence and allergic transfusion reaction (ATR) in patients with blood type O. Design, Setting, and Participants In this international, multicenter, retrospective cohort study at academic medical centers, sites were assigned to AGS high- or low-prevalence clusters based on the known geographic distribution of AGS. Data were collected on platelet or plasma transfusions and ATRs during 2020 to 2024. Consecutive patients receiving platelet or plasma transfusions were included. Exposures Patients with blood type O who received B or AB units and patients with blood type O who received O units (reference group) in AGS high- and low-prevalence clusters were compared. Main Outcomes and Measures Before data collection, the hypothesis was that if transfusion-related alpha-gal syndrome (TRAGS) is a true clinical entity, excess ATRs to group B or AB units would be detected in AGS high-prevalence regions exclusively. The main measure was the overall risk ratio (RR) for ATRs to B or AB plasma or platelets in AGS high- vs low-prevalence clusters. Results In total, 558 823 platelet and plasma transfusions at 40 sites in 5 countries were analyzed, of which ATRs occurred in 1744 transfusions (0.3%). In the US AGS high-prevalence cluster (9 sites), significantly more ATRs of any severity occurred among patients with blood type O who received B or AB units vs patients with blood type O who received O units (overall RR, 3.93; 95% CI, 2.96-5.21; P &amp;lt; .001). In contrast, in the primary analysis of the AGS low-prevalence cluster (15 sites), excess ATRs to B or AB units were not detected. In subgroup analyses among patients with blood type O receiving B units, the RR for moderate to severe ATRs was 9.14 (95% CI, 5.39-15.52; P &amp;lt; .001) in the AGS high-prevalence cluster vs 2.15 (95% CI, 1.34-3.47; P = .002) in the AGS low-prevalence cluster. Outside the US, a signal consistent with TRAGS was not detected. Conclusions and Relevance This cohort study provides provocative epidemiologic evidence that TRAGS may be a unique manifestation of AGS and a previously unrecognized risk associated with transfusion. In AGS high-prevalence regions, blood collectors and hospital transfusion services should consider approaches to preventing severe ATRs from B or AB plasma or platelet units.
Multicenter Evaluation of Noise Levels and Staff Perceptions Across Laser Technologies During Holmium Laser Enucleation of the Prostate: A Prostate Enucleation Collaborative Initiative
Wu, Jessica , Dalkin, Benjamin, Kuravi, Satvik, Cohen, A. , Klose, Charles , Qualkenbush, Eric , Baird, Bryce , Stern, Karen , De, Smita , Klett, Dane, Kahn, Amanda E. , Dalkin, Benjamin , Cohen, Adam , Qualkenbush, Eric , Baird, Bryce A , Stern, Karen L , De, Smita , Jain, Rajat , Quarrier, Scott O , Dora, Chandler D , Jain, Rajat , Dora, Chandler

Mayo Clinic

Lasers in Surgery and Medicine | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/lsm.70197 | PMID 42635390 Get It

ABSTRACT Introduction Operating room (OR) noise during holmium laser enucleation of the prostate (HoLEP), particularly from laser activation, may impair surgical workflow and staff performance. Methods 84 HoLEP procedures were recorded at three academic institutions between June 2024 and January 2026. Laser platforms included Lumenis Moses 2.0, Quanta Litho 150, Quanta Magneto, and Dornier Thulio. Sound measurements were obtained using a standardized smartphone‐based system during three phases: laser‐off (baseline), idle (not firing), and active lasing. Acoustic metrics included average sound level (LAeq), peak sound level (Lcpeak), and sound levels exceeded for 10%, 50%, and 90% of the recording time (L10, L50, and L90). Background noise correction was performed using baseline measurements to account for ambient noise and isolate laser‐related sound. OR staff completed a validated survey assessing perceived noise burden (0–10 scale). Results Background‐corrected noise during active lasing differed significantly by platform. Litho demonstrated lower mean noise levels compared to Thulio for LAeq (60.6 vs. 68.2 dB, p = 0.023) and L10 (61.5 vs. 70.6 dB, p = 0.023), while Moses had higher LAeq compared to Litho (63.1 vs. 60.6 dB, p = 0.043). Overall, Litho had the lowest noise levels, whereas Thulio had the highest. Survey responses paralleled these findings. Litho was associated with lower perceived overall effort (2.1 ± 0.9), while Moses demonstrated higher overall effort (3.6 ± 1.2) for communication and concentration (Figure 2). Significant pairwise differences were observed between Moses and Litho (all p < 0.05). Trends were consistent across sites. Conclusions Noise levels during HoLEP varied by laser technology and correlated with differences in perceived communication and cognitive effort. Litho demonstrated the lowest acoustic burden, while Moses and Thulio had higher noise exposure. These findings highlight the impact of laser selection on the OR environment and intraoperative team performance.
Performance of general-population breast cancer risk prediction models in an international consortium
Brantley, Kristen D. , Ahearn, Thomas U, Norton, Emily , MacInnis, Robert, Palmer, Julie R, Vachon, Celine M, Beane-Freeman, Laura, Frost, Reuben, Zirpoli, Gary, Neuhouser, Marian L, Barnett, Matthew, Teras, Lauren R, Patel, Alpa V, Bodelon, Clara, Spielfogel, Emma S. , Kirsh, Victoria A. , Langseth, Hilde , Milne, Roger L, Haiman, Christopher, Scott, Christopher G, Eliassen, A. Heather, Rosner, Bernard, Willett, Walter C, Chen, Yu, Wu, Fen , Zheng, Wei, Long, Jirong, O'Brien, Katie M, Sandler, Dale P, Linet, Martha S. , Anderson, Garnet, Larson, Joseph C. , Lee, I-Min, Chatterjee, Nilanjan, Kraft, Peter, Brantley, Kristen D , Kirsh, Victoria A , Ahearn, Thomas U. , Norton, Emily L., Palmer, Julie R. , Fortner, Renée T. , Vachon, Celine M. , González, Amy Berrington de , Bertrand, Kimberly A. , Zirpoli, Gary , Barnett, Matthew J , Teras, Lauren R. , Hodge, James M. , Patel, Alpa V , Bodelón, Clara , Lacey, James V. , Rohan, Thomas E. , Tsuruda, Kaitlyn M. , Milne, Roger L , Rosner, Bernard, Willett, Walter C. , Romanos-Nanclares, Andrea , Zheng, Wei , Long, Jirong, O’Brien, Katie M. , Sandler, Dale P. , Kitahara, Cari M. , Anderson, Garnet L. , Lee, I-Min, García‐Closas, Montserrat , Chatterjee, Nilanjan

Mayo Clinic

No container title available | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.20.26360899 Get It

Background: Several breast cancer (BC) risk prediction models have been developed to provide personal risk assessments. Though individually validated, their performance has not been systematically evaluated across a wide range of populations or ages. Methods: We harmonized individual-level baseline questionnaire data and incident BC diagnoses from 21 cohorts from North America, Europe, and Australia participating in the Breast Cancer Risk Prediction Project. Five-year absolute risk of invasive BC was estimated for five established risk prediction models using classical risk factors only. Discrimination was evaluated by area under the curve (AUC). Calibration was assessed using average and risk-decile specific expected to observed (E/O) ratios. Performance metrics were meta-analyzed across cohorts and models. Metaregression tested associations between cohort characteristics and performance metrics. Results: This analysis included 1,595,977 women aged 20-75 years, enrolled in studies between 1976-2015, with 19,062 (1.2%) invasive BC cases ascertained within 5 years from exposure assessment. Age-adjusted AUCs were similar across models and cohorts (pooled AUCs by model: 0.57-0.58), while E/O ratios varied substantially (pooled E/O ratios by model: 0.83-1.25). Overestimation was common among predicted high-risk individuals (>3%). No appreciable differences in model performance by cohort age, birth year, race, and variable missingness emerged. Calibration improved after assigning race-specific incidence rates. Conclusion: Existing BC risk prediction models provided similar risk discrimination across multiple cohorts, although there was overestimation of risk for high-risk individuals. Performance variation across cohorts was not driven by specific characteristics, which supports development of a unified risk model for diverse populations that leverages appropriate incidence rates.